Close this search box.

Welcoming Danielle Meadows, Ph.D., as OMF’s Vice President of Research Programs & Operations

Professional headshot of Danielle Meadows smiling at the camera.I am thrilled to announce that Danielle Meadows, Ph.D., has joined Open Medicine Foundation as our new Vice President of Research Programs & Operations. With her exceptional background and expertise in biomedical engineering, research administration, and project management, Danielle is poised to play a pivotal role in driving our mission forward to find treatments and a cure for ME/CFS and Long COVID.

As we intensify our journey to advance research efforts in ME/CFS and beyond, Danielle’s leadership will be instrumental in synthesizing our research endeavors and propelling us into the next phase of discovery. Her extensive experience in research administration, technical science writing, design of clinical trials, and development of regulatory documents will ensure OMF’s initiatives are executed with precision and excellence.

Danielle’s passion for pioneering research, coupled with her proficiency in areas such as cancer nanomedicine and drug delivery, will enrich
our global team and contribute to our collective efforts in redefining the future of treatment solutions for complex diseases.


University of Delaware, Newark, DE 
Ph.D., Biomedical Engineering 
Doctoral Thesis: “Treating Triple-Negative Breast Cancer Through Nanoparticle-Mediated Photothermal Therapy and Gene Regulation”

University of Notre Dame, Notre Dame, IN
B.S., Chemical and Biomolecular Engineering, Concentration in Biomolecular Engineering

Danielle is joining OMF after her role at CareEvolution as the Senior Scientific Officer and Director of Marketing, Demand Generation. Among other work, Danielle was Project Director for the NIH’s RECOVER Digital Health Platform and Scripps Research’s Long COVID Randomized Controlled Trial.

Danielle has an extensive research background spanning various institutions and projects. At Leidos, she worked on the NIH’s All of Us Research Program as a Project Manager and Biomedical Scientist, supporting the development and implementation of new modules and initiatives within the program.

In her graduate studies at the University of Delaware, Danielle focused on biomedical engineering under the guidance of Dr. Emily S. Day. Her work involved developing biodegradable nanoparticles for photothermal therapy and targeted drug delivery to treat triple-negative breast cancer, using payloads like Notch-1 antibodies, ABT-737, miR-34a, and IR820. She designed, synthesized, and characterized these nanoparticles, conducted in vitro and in vivo studies, wrote manuscripts, and presented their findings at multiple conferences.

During her undergraduate studies at the University of Notre Dame and through a research opportunity at the University of Houston, she contributed to projects studying the development of wings in Drosophila melanogaster larvae and involving mutation analysis of TAL reporters for biosensor optimization, respectively.

Prior to these experiences, Danielle was an independent researcher at the University of Massachusetts Medical School, where she investigated the regulation of the endocycle in D. melanogaster, focusing on the role of cyclin B and the steroid hormone 20-hydroxyecdysone. Her research involved dissection and microscopy techniques, image analysis, and numerous presentations at regional, state, and international science fairs.

Danielle has a diverse research background with expertise in nanoparticle synthesis, cancer therapy, gene regulation, and developmental biology.



Peer-Reviewed Journal Articles

Valcourt DM, Day ES. Dual regulation of miR-34a and Notch signaling in triple-negative breast cancer by antibody/miRNA nanocarriers. Molecular Therapy
– Nucleic Acids. 2020.

Valcourt DM, Kapadia CH, Scully MA, Dang MN, Day ES. Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines. Advanced Healthcare Materials. 2020. Invited submission

Valcourt DM, Dang MN, Scully MA, Day ES. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for
Triple-Negative Breast Cancer. ACS Nano. 2020. DOI:10.1021/acsnano.9b09263

Valcourt DM, Dang MN, Wang J, Day ES. Nanoparticles for manipulation of the developmental Wnt, Hedgehog, and Notch signaling pathways in cancer. Annals
Biomed Eng. 2019. DOI: 10.1007/s10439-019-02399-7. Invited submission to the special issue “Biomaterials – Engineering Cell Fate”. Featured cover

Kapadia CH, Luo B, Dang MN, Irvin-Choy N, Valcourt DM, Day ES. Polymer nanocarriers for microRNA delivery. J App Polymer Sci. 2019. DOI:
10.1002/APP.48651. Invited submission to the special issue “Intelligent/Responsive Polymers as Biomaterials”

Valcourt DM, Dang MN, Day ES. IR820-loaded PLGA nanoparticles for photothermal therapy of triple-negative breast cancer. J Biomed Mater Res A. 2019. DOI: 10.1002/jbm.a.36685 Top downloaded paper 2018-2019

Valcourt DM, Harris J, Riley RS, Dang MN, Wang J, Day ES. Advances in targeted nanotherapeutics: From bioconjugation to biomimicry. Nano Research. 2018 Melamed JR, Riley RS, Valcourt DM, Day ES. Using gold nanoparticles to disrupt the tumor microenvironment: an emerging therapeutic strategy. ACS Nano. 2016. DOI: 10.1021/acsnano.6b07673.
Invited submission

Book Chapters

Melamed JR, Riley RS, Valcourt DM, Billingsley MM, Kreuzberger NL, Day ES. Quantification of siRNA duplexes bound to gold nanoparticle surfaces. In: Biomedical Nanotechnology: Methods and Protocols, 2nd Edition, edited by Sarah Hurst Petrosko and Emily S. Day (Humana Press)

Please join us in extending a warm welcome to Danielle as she embarks on this exciting new chapter with us at Open Medicine Foundation.


Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669